ADMA BIOLOGICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $35.00K, a 98.30% decline year-over-year.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $588.00K, a 482.18% increase year-over-year.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $389.00K, a 93.16% decline year-over-year.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.06M, a 523.56% increase year-over-year.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $2.98M, a 60.18% decline from fiscal 2024.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $7.49M, a 578.80% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.10M, a 530.86% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $175.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $35.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $588.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $2.98M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $389.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $2.06M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $101.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $7.49M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $5.69M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $331.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $1.03M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $1.10M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $624.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $472.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $175.00K 10-K · filed 2025-03-18 | |
| 2020-12-31 | $13.43K 10-K · filed 2022-03-24 | |
| 2020-06-30 | $6.25K 10-Q · filed 2021-11-10 | $13.43K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-03-31 | $7.18K 10-Q · filed 2021-11-10 | $82.22K derived: sum of 4 quarters · filed 2021-11-10 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $75.05K 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $75.05K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $6.68K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $13.01K 10-K · filed 2020-03-13 |
| 2018-03-31 | $0.00 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $7.50K 10-K · filed 2019-03-13 |
| 2015-12-31 | $49.23K 10-K · filed 2017-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |